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Abstract: The clinical success of cisplatin, carboplatin, and oxaliplatin has sparked the interest of
medicinal inorganic chemistry to synthesize and study compounds with non-platinum metal centers.
Despite Ru(II)–polypyridyl complexes being widely studied and well established for their antitumor
properties, there are not enough in vivo studies to establish the potentiality of this type of compound.
Therefore, we report to the best of our knowledge the first in vivo study of Ru(II)–polypyridyl
complexes against breast cancer with promising results. In order to conduct our study, we used
MCF7 zebrafish xenografts and ruthenium complexes [Ru(bipy)2(C12H8N6-N,N)][CF3SO3]2 Ru1
and [{Ru(bipy)2}2(µ-C12H8N6-N,N)][CF3SO3]4 Ru2, which were recently developed by our group.
Ru1 and Ru2 reduced the tumor size by an average of 30% without causing significant signs of
lethality when administered at low doses of 1.25 mg·L−1. Moreover, the in vitro selectivity results
were confirmed in vivo against MCF7 breast cancer cells. Surprisingly, this work suggests that both
the mono- and the dinuclear Ru(II)–polypyridyl compounds have in vivo potential against breast
cancer, since there were no significant differences between both treatments, highlighting Ru1 and
Ru2 as promising chemotherapy agents in breast cancer therapy.
Keywords: ruthenium; polypyridyl compounds; cytotoxicity; cell death; cell cycle; in vivo toxicity;
MCF7 zebrafish xenograft
1. Introduction
Currently, cancer is a pandemic with more than 18,000,000 diagnosed cases [1], being
considered the second leading cause of death worldwide. In fact, in 2020, female breast
cancer surpassed lung cancer as the most diagnosed cancer with 2.3 million new cases [2],
and specific types of breast cancer are today still incurable [3]. Despite the improved
knowledge of breast cancer biology and the great advances in targeted and immuno-
oncological therapies, cytotoxic chemotherapy, such as cisplatin and its derivatives, remains
central to breast cancer treatment [3,4]. However, the high toxicity and the acquired or
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intrinsic drug resistance remain the main limitations in the clinical application of platinum-
based treatments [5]. Thus, the development of new chemotherapeutic agents is critical
for further progress in cancer treatment. In this context, ruthenium-based compounds
are an attractive alternative to platinum compounds since they exhibit excellent results as
potential anticancer drugs [6].
In particular, both mono- and dinuclear Ru(II)–polypyridyl complexes have attracted
attention for the development of new therapeutic agents against cancer, and this fact is very
interesting since the compound TLD-1433 (Figure 1) is in clinical trials for the treatment of
noninvasive bladder cancer of the muscles (clinical trial NCT03945162) [7].
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However, there are currently insufficient in vivo studies to allow for an effective eval-
uation of the full potential of this class of compounds [8,9]. Furthermore, for some cancers, 
such as breast cancer, the Ru(II)–polypyridyl complexes have been less explored [8,10]. 
The ruthenium compounds reported against breast cancer are generally organometallic 
compounds [10], e.g., ruthenium arene [11–21] and cyclopentadienyl [22–26] compounds, 
which have also been less explored in vivo. 
Mouse xenografts are a powerful tool for drug development, but zebrafish has also 
attracted attention as a model in drug discovery. In particular, the larval zebrafish xeno-
graft is ideal for drug discovery and differs fundamentally from mouse xenografts in that 
larval xenograft assays can be done in a short time (up to 5 days post transplant) [27–30]. 
There are also significant experimental advantages, including high-resolution intravital 
imaging and high-throughput 96-well format drug screening [27]. Moreover, there is no 
need for immunosuppression because larval zebrafish do not develop a functional adap-
tive immune system until 4–6 weeks post fertilization [29]. 
Our group recently synthesized and characterized mononuclear and dinuclear com-
pounds derived from the Ru(bipy)2 fragment [31,32]. We demonstrated the cytotoxic ac-
tivity of Ru1 and Ru2 (Figure 2) against human breast tumor MCF7 cells with IC50 values 
of 25.4 ± 5.0 and 30.1 ± 12.5 μM, respectively. No cytotoxicity in normal human primary 
fibroblasts in the case of Ru1 was observed [31], while a cytotoxicity analysis of Ru2 for 
normal cells was not performed. Both compounds interact with ctDNA, with Ru2 specif-
ically showing a concentration-dependent double-strand cleavage of plasmidic DNA 
[31,32]. 
As a result of the in vitro results that we obtained and the urgent need for new breast 
cancer treatments, we decided to not only study in more detail the anticancer activity of 
the Ru(II)–polypyridyl complexes Ru1 and Ru2 against a breast cancer cell line, MCF7, 
but also investigate the in vivo anticancer activity of the Ru complexes through larval 
zebrafish MCF7 xenografts, which to the best of our knowledge represents the first in vivo 
study of Ru(II)–polypyridyl complexes against breast cancer. 
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However, there are currently insufficient in vivo studies to allow for an effective eval-
uation of the full potential of this class of compounds [8,9]. Furthermore, for some cancers,
such as breast cancer, the Ru(II)–polypyridyl complexes have been less explored [8,10].
The ruthenium compounds reported against breast cancer are generally organometallic
compounds [10], e.g., ruthenium arene [11–21] and cyclopentadienyl [22–26] compounds,
which have also been less explored in vivo.
Mouse xenografts are a powerful tool for drug development, but zebrafish has also
attracted attention as a model in drug discovery. In particular, the larval zebrafish xenograft
is ideal for drug discovery and differs fundamentally from mouse xenografts in that larval
xenograft assays can be done in a short time (up to 5 days post transplant) [27–30]. There
are also significant experimental advantages, including high-resolution intravital imaging
and high-throughput 96-well format drug screening [27]. Moreover, there is no need for
immunosuppression because larval zebrafish do not develop a functional adaptive immune
system until 4–6 weeks post fertilization [29].
Our group recently synthesized and characterized mononuclear and dinuclear com-
pounds derived from the Ru(bipy)2 fragment [31,32]. We demonstrated the cytotoxic
activity of Ru1 and Ru2 (Figure 2) against human breast tumor MCF7 cells with IC50
values of 25.4 ± 5.0 and 30.1 ± 12.5 µM, respectively. No cytotoxicity in normal human
primary fibroblasts in the case of Ru1 was observed [31], while a cytotoxicity analysis
of Ru2 for normal cells was not performed. Both compounds interact with ctDNA, with
Ru2 specifically showing a concentration-dependent double-strand cleavage of plasmidic
DNA [31,32].
As a result of the in vitro results that we obtained and the urgent need for new breast
cancer treatments, we decided to not only study in more detail the anticancer activity of
the Ru(II)–polypyridyl complexes Ru1 and Ru2 against a breast cancer cell line, MCF7, but
also investigate the in vivo anticancer activity of the Ru complexes through larval zebrafish
MCF7 xenografts, which to the best of our knowledge represents the first in vivo study of
Ru(II)–polypyridyl complexes against breast cancer.
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Figure 3. Effect of Ru2 on cellular viability of nontumor cell line fibroblasts. Cells were exposed to
0.5–100 µM of ompo nd or 0.1% (v/v) DMSO (vehicle control) for 72 h. The results are expressed as
mean ± SEM fold-change c mpared to controls of at least three independent xperiments.
2.2. Cell Death Mechanism
To gain insight i to the mechanism of cytotoxic action induced after 72 h exposure
of the MCF7 cell line to both Ru(II) mononuclear and dinuclear compounds, the level of
apoptosis was evaluated by assessing Hoechst nuclei staining in the absence (DMSO as
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vehicle control) or presence of compounds (at IC50). Hoechst 33258 (2′-[4-ethoxyphenyl]-5-
[4-methyl-1-piperazinyl]-2,5′-bi-1H-benzimidazole trihydrochloridetrihydrate) has a high
affinity for nucleic acids, allowing the detection of nuclear alterations [36]. The nuclei of
viable cells exhibit a blue fluorescence distributed homogeneously, whereas apoptotic cells
exhibit apoptotic bodies, nuclear fragmentation, and chromatin condensation, revealing a
higher fluorescence intensity [36]. As observed in Figure 4A, an increase in the number
of apoptotic markers, such as fragmentation and chromatin condensation was observed
in MCF7 cells incubated in the presence of both compounds, corresponding to 41% ± 3%
apoptotic cells for Ru1 (4.1-fold increase over the control) and 45% ± 4% apoptotic cells for
Ru2 (4.5-fold increase over the control) (Figure 4B).
Int. J. Mol. Sci. 2021, 22, x FOR PEER REVIEW 4 of 13 
 
 
apoptosis was evaluated by assessing Hoechst nuclei staining in the absence (DMSO as 
vehicle control) or presence of compounds (at IC50). Hoechst 33258 (2′-[4-ethoxyphenyl]-
5-[4-methyl-1-piperazinyl]-2,5′-bi-1H-benzimidazole trihydrochloridetrihydrate) has a 
high affinity for nucleic acids, allowing the detection of nuclear alterations [36]. The nuclei 
of viable cells exhibit a blue fluorescence distributed homogeneously, whereas apoptotic 
cells exhibit apoptotic bodies, nuclear fragmentation, and chromatin condensation, reveal-
ing a higher fluorescence intensity [36]. As observed in Figure 4A, an increase in the num-
ber of apoptotic markers, such as fragmentation and chromatin condensation was ob-
served in MCF7 cells incubated in the presence of both compounds, corresponding to 41% 
± 3% apoptotic cells for Ru1 (4.1-fold increase over the control) and 45% ± 4% apoptotic 
cells for Ru2 (4.5-fold increase over the control) (Figure 4B). 
 
Figure 4. (A) Hoechst staining (excitation and fluorescence emission at 352 and 461 nm, respectively) of MCF7 cell line for 
visualization of apoptotic nuclei. Cells were grown in DMEM culture medium supplemented with 10% (v/v) fetal bovine 
serum in the presence of 0.1% (v/v) DMSO, the IC50 of cisplatin, the IC50 of Ru1, or the IC50 of Ru2 for 72 h. The arrows indicate 
an initial event of apoptosis such as chromatin condensation and nuclear fragmentation. The images were acquired using a 
ZEISS Microscope with ZEN software. (B) Percentage of apoptotic cells in MCF7 breast adenocarcinoma cell line after expo-
sure to 0.1% (v/v) DMSO (vehicle control) or to the IC50 of each Ru(II) compound. The data are presented as the mean ± SEM 
of three independent experiments, and the statistical significance was evaluated in relation to the reference group (control) 
using the one-way ANOVA method followed by a Tukey multiple comparison test (**** p ≤ 0.0001). 
Both compounds were previously described to induce apoptosis in ovarian carci-
noma cell line A2780 [31,32]. The results presented in this study confirm that both mono-
nuclear and dinuclear Ru(II) compounds can induce apoptosis in MCF7 cancer cells. 
2.3. Cell-Cycle Progression 
In addition to the cytotoxic effect, several antitumor drugs also demonstrate a high 
cytostatic potential [37,38]. To analyze the cytostatic potential of Ru1 and Ru2, MCF7 cells 
were synchronized at the G1/S phase, and then the cell-cycle progression of untreated and 
compound-treated MCF7 cells (for 6 h and 12 h) was evaluated by flow cytometry using 
propidium iodide (PI) fluorescence. 
Flow cytometry analysis at 12 h showed that in untreated samples, most cells were 
in the G0/G1 phase (76.2%), whereas Ru1-treated cells showed a lower percentage of cells 
Figure 4. (A) Hoechst staining (excitation and fluorescence emission at 352 and 461 nm, respectively) of MCF7 cell line for
visualization of apoptotic nuclei. Cells were grown in DMEM culture medium supplemented with 10% (v/v) fetal bovine
serum in the presence of 0.1% (v/v) DMSO, the IC50 of cisplatin, the IC50 of Ru1, or the IC50 of Ru2 for 72 h. The arrows
indicate an initial event of apoptosis such as chromatin condensation and nuclear fragmentation. The i ages were acquired
using a ZEISS Microscope wit ZEN softwa e. (B) Percentage of apopt tic cells in MCF7 breast ad ocarcinoma cell line
after exposur to 0.1% (v/v) DMSO (vehicle con rol) or to the IC50 of each R (II) compound. The data are presented as the
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Both compounds were previously de cribed to induce apoptosis in ovarian carcinoma
cell line A2780 [31,32]. The results resented i this study confirm that both mononuclear
and dinuclear Ru(II) compounds can induce apoptosis in MCF7 cancer cells.
2.3. Cell-Cycle Progression
In addition to the cytotoxic effect, several antitumor drugs also demonstrate a high
cytostatic potential [37,38]. To analyze the cytostatic potential of Ru1 and Ru2, MCF7 cells
were synchronized at the G1/S phase, and then the cell-cycle progression of untreated and
compound-treated MCF7 cells (for 6 h and 12 h) was evaluated by flow cytometry using
propidium iodide (PI) fluorescence.
Flow cytometry analysis at 12 h showed that in untreated samples, most cells were in
the G0/G1 phase (76.2%), whereas Ru1-treated cells showed a lower percentage of cells in
the G0/G1 phase (58.7%) and an increase in the number of cells in the G2/M phase (23.9%)
(Figure 5).
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In the case of Ru2-treated cells, there was a difference in the S phase (9.8%) at 12 h
when compared to control cells (16.6%), which was associated with an increase in the
number of cells in the G2/M phase (22.1%) (Figure 5).
These results suggest that both compounds cause a slight delay in MCF7 cell-cycle
progression, which agrees with our previous results, where both Ru1 and Ru2 showed the
ability to interact in vitro with DNA [31,32].
2.4. Subcellular Distribution
The knowledge of the subcellular distribution of the compound is fundamental in the
elucidation of its mechanism of action [39]. The intracellular distribution of the compounds
in the MCF7 cell line was studied using the Cell Fractionation Kit-Standard (ab109719,
Abcam, Cambridge, UK). This kit allows the separation of cytosolic, mitochondrial, and
nuclear fractions using detergents that take advantage of the characteristics and composi-
tion of different cell membranes. For both samples, the ruthenium content was determined
using inductively coupled plasma atomic emission spectroscopy (ICP-AES) technique. We
used at least 2× the IC50 concentration since the detection limits of ICP-AES did not allow
us to use their respective IC50. After 6 h incubation, only 0.76% of Ru1 and 0.71% of Ru2
was found to be internalized by cells. As observed in Figure 6, when only considering
the percentage of internalized compounds, both Ru1 and Ru2 were distributed among the
cytosolic, mitochondrial, and nuclear fractions. No significant difference was observed
in the amount of ruthenium among the three subcellular fractions (Figure 6). This distri-
bution among the different fractions might indicate that these compounds might target
different cell lar components, in addition to DNA, which may contribute to the mechanism
underlying their antiproliferative effect.
2.5. In Vivo Assays
Preliminary toxicity assays on 48 h post fertilization (hpf) embryos at 34 ◦C were
carried out in this work with the LC10 (lethal dose 10%) obtained from previous analy-
ses [30,31]. This led to very high mortality rates. Then, new conditions were evaluated to
identify the highest safe concentration in zebrafish embryos from 48 hpf onward, at 34 ◦C,
dissolved in 1% (v/v) DMSO/water. In the end, the same concentration was chosen for
both compounds (1.25 mg·L−1), showing low mortality rates for the first 72 h of exposition
(Figure 7). No significant effects were found compared to controls for this period of time.
For longer exposures, mortality was higher in those embryos exposed to any concentration
of the drugs than the control.
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Then, an outlier analysis was run, which detected one outlier in the control group, none
in the Ru1 group, and three in the Ru2 group. Results indicated that both experimental
treatments significantly reduced the cancer cell population in the embryos (0.89 ± 0.37
and 0.96 ± 0.27 for Ru1 and Ru2 respectively) compared to controls (1.33 ± 0.46). No
statistical differences were found between treatments, showing a slightly bigger reduction
for Ru1 (Figure 9).
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Therefore, from the model species point of view, xenograft assays demonstrated
that both newly developed antitumor drugs effectively prevented MFC7 proliferation,
supporting the medicinal properties recognized for ruthenium–polypyridyl complex-based
compounds [40–42]. Lastly, given the genetic and molecular similarities between zebrafish
and human beings [43], and the predictability of zebrafish for the effect of drugs on other
species, including humans [44], the compounds studied prove to be potential candidates
for chemotherapeutic agents because of their safety and effectiveness. Therefore, both
compounds demonstrated potential for further in vivo mice biological studies, as well
as for their use as lead scaffolds for further chemical modifications to improve drug-like
properties.
3. Materials and Methods
3.1. In Vitro Assays
3.1.1. Cell Culture and Maintenance
The MCF7 cell line (breast cancer) expressing green fluorescent protein (GFP) (Cell
Biolabs, Inc, San Diego, CA, USA) was used in this work. MCF7 cancer cells were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen, NY, USA) supplemented
with 10% (v/v) fetal bovine serum (FBS) and 1% (v/v) penicillin–streptomycin (Invitrogen,
New York, NY, USA) and maintained at 37 ◦C in a humidified atmosphere of 5% (v/v) CO2.
Normal human primary fibroblasts were grown in the same conditions as the MCF7 cell
line, supplemented with 1% (v/v) MEM nonessential amino acids (Invitrogen) [35,45]. The
fibroblast cell line was purchased from ATCC (www.atcc.org, 28 June 2021).
3.1.2. Cytotoxic Activity Assay in Normal Human Fibroblasts and MCF7
The antiproliferative activity was evaluated in human normal fibroblasts using the
CellTiter 96® Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, WI,
USA) and the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium inner salt (MTS) as previously described [35,45]. MCF7 cells and normal
human fibroblasts were plated into 96-well plates at 0.75 × 105 cells/well and allowed to
adhere for 24 h. Then, DMEM medium was removed and replaced with fresh medium
containing 0.5–100 µM compounds, 0.1–100 µM cisplatin, 0.1% (v/v) DMSO (vehicle control
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of compounds), or 0.09% (w/v) NaCl (vehicle control of cisplatin) and incubated in the
same conditions. After 72 h of treatment, the medium was replaced by the MTS solution
and the subsequent experimental procedures followed a previously described method [37].
Cell viability was evaluated by measuring the absorbance at 490 nm using a Bio-Rad
microplate reader, model 680 (Bio-Rad, Hercules, CA, USA).
3.1.3. Hoechst 33258 Staining
MCF7 cells were collected and plated in a 24-well culture slide at 0.75 × 105 cells/mL.
The culture medium was removed 24 h after plating and replaced with the IC50 of cisplatin
(positive control), Ru1, or Ru2, or 0.1% (v/v) DMSO (vehicle control) diluted in fresh
medium. Following 72 h of treatment, cells were stained with Hoechst 33258 (excitation
and fluorescence emission at 352 and 461 nm, respectively) in the absence of light for 15 min,
at room temperature, according to the procedure described in [46]. Fluorescent nuclei
were analyzed on the basis of the chromatin condensation degree and other characteristics.
Normal nuclei showed uncondensed chromatin uniformly distributed over the entire
nucleus. Apoptotic nuclei showed condensed or fragmented chromatin. In addition, some
cells formed apoptotic bodies. The samples were photographed using a Zeiss fluorescence
microscope and the photographs were acquired with Zen Blue edition software. Three
random microscopic fields per sample with ca. 50 nuclei were counted. Mean values were
expressed as the percentage of apoptotic nuclei.
3.1.4. Cell-Cycle Analysis
MCF7 cells were seeded into an eight-well culture slide at 1 × 105 cells/mL and incu-
bated for 24 h at 37 ◦C, 99% (v/v) humidity, and 5% (v/v) CO2, before being synchronized
in the early S phase by double thymidine block (2 mM) (Sigma, St. Louis, MO, USA)
as described previously [45]. Cells were released from the second block by substituting
with fresh medium containing the IC50 concentration of Ru1 or Ru2, or 0.1% (v/v) DMSO
(vehicle control), and they were incubated for 6 or 12 h at 37 ◦C and 5% (v/v) CO2. For
synchronization control purposes, cells from another disc were collected after thymidine
block. After each time point, cells were trypsinized with TrypLETM Express and centrifuged
(5 min, 650× g, 4 ◦C). Supernatants were removed, and cell pellets were resuspended in
phosphate-buffered saline (PBS) 1×. An additional centrifugation was performed (5 min,
650× g, 4 ◦C), and the pellets were resuspended in PBS 1× and ethanol 80% (v/v) (1:10
proportion). The ethanol solution was added gently with constant agitation. Cells were
stored at 4 ◦C for at least 12 h. After incubation, cells were centrifuged (10 min, 5000× g,
4 ◦C), and the pellet was treated with 50 µg/mL RNase A for 30 min at 37 ◦C and PI
(25 µg/mL, excitation and fluorescence emission at 493 and 636 nm, respectively). The
DNA content was analyzed using an Attune® Acoustic Focusing Flow Cytometer (Applied
Biosystems, Waltham, MA, USA), and the data collected were analyzed with FCS Express 6
Flow Cytometry software.
3.1.5. Subcellular Distribution
For subcellular fractionation, MCF7 cells were seeded in 25 cm2 culture flasks at a cell
density of 1 × 106 cells/flask and incubated for 24 h at 37 ◦C, 99% (v/v) humidity, and 5%
(v/v) CO2. After 24 h incubation, the medium was replaced with 5 mL of fresh medium
containing 60 µM Ru1 or Ru2 (a concentration high enough to be detected) and incubated
for 6 h at 37 ◦C. After incubation, the supernatant was collected; cells were detached from
the culture flask and pelleted at 500× g for 5 min. Then, the cytosolic, mitochondrial
and nuclear fractions were sequentially isolated using the Cell Fractionation Kit Standard
(Abcam, Cambridge, MA, USA) according to the manufacturer’s instructions. Afterward,
aqua-regia (HNO and HCl in a 1:3 proportion) was added to the four fractions in 1:2
proportion (aqua regia–sample volume) and samples were incubated overnight at room
temperature. The four fractions were then analyzed using a Horiba Jobin Yvon inductively
coupled plasma atomic emission spectrometer as a paid service (Analytical Laboratory,
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Department of Chemistry, FCT-UNL) to determine the amount of ruthenium present in
each sample.
3.1.6. Statistical Analysis
All data were expressed as the mean ± SEM of at least three independent biological
experiments. Statistical significance was evaluated using Student’s t-test and one-way
ANOVA followed by a Tukey multiple comparison test; a p-value <0.05 was considered
statistically significant.
3.2. In Vivo Assays
3.2.1. Zebrafish Maintenance
Adult zebrafish (wild-type) were maintained at 28.5 ◦C with a light/dark cycle of
14/10 h following The Zebrafish Book recommendations (Westerfield, 2007). Embryos
were obtained as massive spawning and were maintained in purified and dechlorinated
water (water). In both toxicity and xenograft experiments, zebrafish embryos were kept at
28 ◦C until the experiments began, at which point the embryos were raised at 34 ◦C.
3.2.2. Toxicological Analysis
Toxicological analyses were previously developed on zebrafish embryos for full char-
acterization of the compounds [30,31], following the OECD standardized protocol [47].
Nevertheless, due to the differences in the experimental conditions applied in the original
toxicological evaluations to those applied here, new assays were developed. The embryo
initial stage was delayed from 0 hpf to 48 hpf, the temperature was raised from 28 to 34 ◦C
in 96-well plates, and the compounds were dissolved in 1% (v/v) DMSO water. After pre-
liminary trials, both compounds were tested at 1.25, 2.50, 5, and 10 mg·L−1. Survival was
checked every 24 h from 0 hpt (i.e., 48 hpf) to 120 hpt (168 hpf). The highest concentration
without significant effects (high phenotypic effects or low survival) was chosen for each
compound to expose the xenografted embryos and to evaluate the effect on the cancer cell
population.
3.2.3. Zebrafish Xenografts
The MCF7 cell line expressing GFP was used in this work to develop the xenograft
model. Breast cancer cells were cultured in DMEM supplemented with 10% (v/v) FBS
and 1% (w/v) penicillin–streptomycin (Gibco, ThermoFisher Scientific, Waltham, MA,
USA). Cells were detached from the culture flask, and approximately 1 × 106 cells were
concentrated in 10 µL of 2% PVP40 (Sigma, Madrid, Spain) in PBS. Next, 15–20 nL of this
cell suspension was microinjected in the yolk of 48 hpf zebrafish embryos. To improve
the proliferation of MCF7, taking into account zebrafish embryo survival, the incubation
temperature was set to 34 ◦C.
Embryos recovered from microinjection for 24 h, which also favored tumor cell prolifer-
ation. After that time, embryos without cells properly injected were discarded. Remaining
individuals were randomly separated into three different groups: 48 individuals exposed to
Ru1, 48 exposed to Ru2, and 10 noninjected and nonexposed embryos used as the control.
Proper concentration of the ruthenium compounds was dissolved as in the toxicological
analysis. Injected individuals were photographed just prior to drug exposition and 24 h
later. Pictures were taken using a Nikon AZ100 zoom microscope, with a filter for GFP
detection (509 nm). Exposition was fixed at 300 ms. Quantifish 1.0 software was used to
obtain the fluorescence information of each image [47]. Then, the proliferation ratio was
calculated for each individual. IBM SPSS Statistics v.24 software was used for the detection
of outliers and for treatment comparisons (One-way ANOVA).
All experiments were carried out under current legislation. Zebrafish in their early
stages (<120 hpf) are not protected according to the European Union Directive 2010/63/EU.
Experiments were performed in agreement and with the approval of the Animal Care and
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Use Committee of the University of Santiago de Compostela. All surviving individuals
were euthanized by tricaine (MS-222) overdose.
4. Conclusions
Both Ru1 and Ru2 complexes were active in the in vivo treatment of breast cancer.
In fact, both compounds inhibited tumor growth by an average of 30% compared to
control in MCF7 zebrafish xenografts. Furthermore, there were no significant signs of
lethality observed. Therefore, there was in vivo selectivity toward cancer cells, and this
result was also observed in vitro. Moreover, both complexes caused cell death through
apoptosis pathways, along with a slight delay in cell-cycle progression. Nonetheless, it
cannot be excluded that these compounds might induce other types of cell death, such
as autophagy, as observed in ovarian cancer cell line A2780 after exposure to Ru1 and
Ru2. Subcellular distribution results suggest that DNA is not the only target for these
compounds, despite their high affinity for DNA, as suggested in previously published
studies [31,32]. Furthermore, both mono- and dinuclear Ru(II) compounds have potential
as chemotherapy agents against breast cancer since no significant differences were found
between treatments with Ru1 and Ru2; consequently, this lays the foundation for the
design of new ruthenium–polypyridyl compounds against cancer.
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